Analyst: WuXi's joint venture with AZ will take time to pay off

CRO WuXi AppTec ($WX) inked a deal to form a joint venture with AstraZeneca's ($AZN) MedImmune last week, and an analyst said the agreement will likely drive up front-end costs for the Chinese company. William Blair's John Kreger tells Outsourcing-Pharma that the CRO will have to ramp up its trial spending over the next few years, likely driving down earnings until the venture has a marketable drug. Report

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.